A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

Trial Profile

A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Jul 2017

At a glance

  • Drugs Ribociclib (Primary) ; Fulvestrant; Goserelin; Letrozole; Tamoxifen
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 28 Jun 2017 Planned End Date changed from 12 Apr 2019 to 5 Oct 2018.
    • 28 Jun 2017 Planned primary completion date changed from 12 Apr 2019 to 6 Sep 2018.
    • 17 Apr 2017 Planned End Date changed from 14 Jun 2019 to 12 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top